

2019-nCoV Spike protein RBD (S477N) Catalog No: C19SD-G238H

Within the Spike protein RBD domain of SARS-CoV-2, S447 is the most commonly mutated residue and S477N mutation occurs very frequently alongside the D614G variant. MD simulation studies suggest that S477N strengthens the binding of the SARS-COV-2 spike with the hACE2 receptor. Hence, as the new variants displace the first-wave virus, it is pivotal to evaluate their transmissibility, virulence and their possible tendency to escape antibody neutralization. SignalChem's Recombinant 2019-nCoV Spike protein S1 subunit, RBD (S477N) (319-541) was expressed in CHO cells using a C-terminal his tag.

Unique Selling Points



Biologically Active



stratech.co.uk/signalchem info@stratech.co.uk

QA/QC tested





Purity approx. 90%

High binding to hACE2

Competitors



a biotechne brand





Researchers analyzing S477N Neutralization opharma developi







Government research organizations

Diagnostic kits R&D

Scientists testing COVID19 inhibitors



Target Customers

Biopharma developing S477N targeting therapies

